NMDA receptors: Recent insights and clinical correlations

Neurology

Volumn 76, Issue 20, 2011, Pages 1750-1757

  Benarroch, Eduardo E ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; AMANTADINE; CALCIUM ION; CYCLOSERINE; DEXTROMETHORPHAN; DIMEBON; KETAMINE; LEVODOPA; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 3; N METHYL DEXTRO ASPARTIC ACID RECEPTOR ANTIBODY; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NERAMEXANE; PHENCYCLIDINE; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ALLOSTERISM; ALZHEIMER DISEASE; ARTICLE; CALCIUM TRANSPORT; CELL SURVIVAL; CHANNEL GATING; DRUG MECHANISM; DRUG PROTEIN BINDING; DYSKINESIA; ENCEPHALITIS; HUMAN; LONG TERM DEPRESSION; LONG TERM POTENTIATION; LOW DRUG DOSE; NERVE CELL NETWORK; NERVE CELL PLASTICITY; NEUROTOXICITY; PAIN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE; RETT SYNDROME; SIGNAL TRANSDUCTION;

ANIMALS; CALCIUM; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; GLUTAMIC ACID; HUMANS; ION CHANNEL GATING; ION CHANNELS; N-METHYLASPARTATE; NERVE NET; NERVOUS SYSTEM DISEASES; NEURONAL PLASTICITY; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 79957525471     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31821b7cc9     Document Type: Article

References (54)

1. Cull-Candy S, Brickley S, Farrant M. NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol 2001;11:327-335. (Pubitemid 32524098)
2. Yamakura T, Shimoji K. Subunit- and site-specific pharmacology of the NMDA receptor channel. Prog Neurobiol 1999;59:279-298. (Pubitemid 29325000)
3. Paoletti P, Neyton J. NMDA receptor subunits: function and pharmacology. Curr Opin Pharmacol 2007;7:39-47. (Pubitemid 46238036)
4. Lau CG, Zukin RS. NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat Rev Neurosci 2007;8:413-426. (Pubitemid 46789232)
5. Waxman EA, Lynch DR. N-methyl-D-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease. Neuroscientist 2005;11:37-49. (Pubitemid 40223089)
6. Hardingham GE, Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci 2010;11:682-696.
7. Chen HS, Lipton SA. The chemical biology of clinically tolerated NMDA receptor antagonists. J Neurochem 2006;97:1611-1626. (Pubitemid 43873656)
8. Kalia LV, Kalia SK, Salter MW. NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol 2008;7:742-755. (Pubitemid 351957932)
9. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDAreceptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008;7:1091-1098.
10. Lipton SA. NMDA receptors, glial cells, and clinical medicine. Neuron 2006;50:9-11.
11. Collingridge GL, Olsen RW, Peters J, Spedding M. A nomenclature for ligand-gated ion channels. Neuropharmacology 2009;56:2-5.
12. Rigby M, Le Bourdelles B, Heavens RP, et al. The messenger RNAs for the N-methyl-D-aspartate receptor subunits show region-specific expression of different subunit composition in the human brain. Neuroscience 1996;73:429-447. (Pubitemid 26168802)
13. Mayer ML. Glutamate receptors at atomic resolution. Nature 2006;440:456-462.
14. Henson MA, Roberts AC, Perez-Otano I, Philpot BD. Influence of the NR3A subunit on NMDA receptor functions. Prog Neurobiol 2010;91:23-37.
15. Matsuda K, Fletcher M, Kamiya Y, Yuzaki M. Specific assembly with the NMDA receptor 3B subunit controls surface expression and calcium permeability of NMDA receptors. J Neurosci 2003;23:10064-10073. (Pubitemid 37392553)
16. Gardoni F. MAGUK proteins: new targets for pharmacological intervention in the glutamatergic synapse. Eur J Pharmacol 2008;585:147-152.
17. Collins MO, Husi H, Yu L, et al. Molecular characterization and comparison of the components and multiprotein complexes in the postsynaptic proteome. J Neurochem 2006;97(suppl 1):16-23.
18. Wang H, Hu Y, Tsien JZ. Molecular and systems mechanisms of memory consolidation and storage. Prog Neurobiol 2006;79:123-135. (Pubitemid 44262439)
19. Mann EO, Mody I. Control of hippocampal gamma oscillation frequency by tonic inhibition and excitation of interneurons. Nat Neurosci 2010;13:205-212.
20. Malenka RC, Bear MF. LTP and LTD: an embarrassment of riches. Neuron 2004;44:5-21. (Pubitemid 39348827)
21. Middleton S, Jalics J, Kispersky T, et al. NMDA receptordependent switching between different gamma rhythmgenerating microcircuits in entorhinal cortex. Proc Natl Acad Sci USA 2008;105:18572-18577.
22. Wang H, Stradtman GG 3rd, Wang XJ, Gao WJ. A specialized NMDA receptor function in layer 5 recurrent microcircuitry of the adult rat prefrontal cortex. Proc Natl Acad Sci USA 2008;105:16791-16796.
23. Taghibiglou C, Martin HG, Lai TW, et al. Role of NMDA receptor-dependent activation of SREBP1 in excitotoxic and ischemic neuronal injuries. Nat Med 2009;15: 1399-1406.
24. Hardingham GE. Coupling of the NMDA receptor to neuroprotective and neurodestructive events. Biochem Soc Trans 2009;37:1147-1160.
25. Arundine M, Tymianski M. Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury. Cell Mol Life Sci 2004;61:657-668. (Pubitemid 38446410)
26. Walker M. Neuroprotection in epilepsy. Epilepsia 2007; 48(suppl 8):66-68. (Pubitemid 350045530)
27. Fan MM, Raymond LA. N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog Neurobiol 2007;81:272-293. (Pubitemid 46528641)
28. Wenk GL, Parsons CG, Danysz W. Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine. Behav Pharmacol 2006;17:411-424. (Pubitemid 44325803)
29. Bagetta V, Ghiglieri V, Sgobio C, Calabresi P, Picconi B. Synaptic dysfunction in Parkinson's disease. Biochem Soc Trans 2010;38:493-497.
30. Li W, Huang Y, Reid R, et al. NMDA receptor activation by HIV-Tat protein is clade dependent. J Neurosci 2008; 28:12190-12198.
31. Matute C. Oligodendrocyte NMDA receptors: a novel therapeutic target. Trends Mol Med 2006;12:289-292. (Pubitemid 44110002)
32. Stys PK, Lipton SA. White matter NMDA receptors: an unexpected new therapeutic target? Trends Pharmacol Sci 2007;28:561-566.
33. Tu W, Xu X, Peng L, et al. DAPK1 interaction with NMDA receptor NR2B subunits mediates brain damage in stroke. Cell 2010;140:222-234.
34. Milnerwood AJ, Gladding CM, Pouladi MA, et al. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron 2010;65:178-190.
35. Chase TN. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology 1998; 50:S17-S25. (Pubitemid 28223748)
36. Attal N, Bouhassira D. Mechanisms of pain in peripheral neuropathy. Acta Neurol Scand Suppl 1999;173:12-24, discussion 48-52. (Pubitemid 29421957)
37. Brenner GJ, Ji RR, Shaffer S, Woolf CJ. Peripheral noxious stimulation induces phosphorylation of the NMDA receptor NR1 subunit at the PKC-dependent site, serine- 896, in spinal cord dorsal horn neurons. Eur J Neurosci 2004;20:375-384. (Pubitemid 38969623)
38. Kurup P, Zhang Y, Xu J, et al. Abeta-mediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61. J Neurosci 2010;30:5948-5957.
39. Chen Y, Durakoglugil MS, Xian X, Herz J. ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling. Proc Natl Acad Sci USA 2010;107:12011-12016.
40. Balu DT, Coyle JT. Neuroplasticity signaling pathways linked to the pathophysiology of schizophrenia. Neurosci Biobehav Rev 2010;35:848-870.
41. Hakami T, Jones NC, Tolmacheva EA, et al. NMDA receptor hypofunction leads to generalized and persistent aberrant gamma oscillations independent of hyperlocomotion and the state of consciousness. PLoS One 2009;4:e6755.
42. Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 2007;27: 11496-11500. (Pubitemid 350006886)
43. Hahn CG, Wang HY, Cho DS, et al. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med 2006;12:824-828.
44. Wandinger KP, Saschenbrecker S, Stoecker W, Dalmau J. Anti-NMDA-receptor encephalitis: a severe, multistage, treatable disorder presenting with psychosis. J Neuroimmunol 2011;231:86-91.
45. Johnson N, Henry C, Fessler AJ, Dalmau J. Anti-NMDA receptor encephalitis causing prolonged nonconvulsive status epilepticus. Neurology 2010;75:1480-1482.
46. Gonzalez-Valcarcel J, Rosenfeld MR, Dalmau J. [Differential diagnosis of encephalitis due to anti-NMDA receptor antibodies.] Neurologia 2010;25:409-413.
47. Kleinig TJ, Thompson PD, Matar W, et al. The distinctive movement disorder of ovarian teratoma-associated encephalitis. Mov Disord 2008;23:1256-1261.
48. Florance NR, Davis RL, Lam C, et al. Anti-N-methyl-Daspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 2009;66:11-18.
49. Hughes EG, Peng X, Gleichman AJ, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 2010;30:5866-5875.
50. Lipton SA. Pathologically activated therapeutics for neuroprotection. Nat Rev Neurosci 2007;8:803-808. (Pubitemid 47462118)
51. Thomas SJ, Grossberg GT. Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias. Clin Interv Aging 2009;4:367-377.
52. Varanese S, Howard J, Di Rocco A. NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off " phenomena in Parkinson's disease. Mov Disord 2010;25:508-510.
53. Crosby NJ, Deane KH, Clarke CE. Amantadine for dyskinesia in Parkinson's disease. Cochrane Database Syst Rev 2003:CD003467.
54. Collins S, Sigtermans MJ, Dahan A, Zuurmond WW, Perez RS. NMDA receptor antagonists for the treatment of neuropathic pain. Pain Med 2010;11:1726-1742.